Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M217Revenue $M0.2Net Margin (%)0Z-Score6.3
Enterprise Value $M158EPS $-0.6Operating Margin %0F-Score1
P/E(ttm))0Cash Flow Per Share $0Pre-tax Margin (%)0Higher ROA y-yN
Price/Book3.510-y EBITDA Growth Rate %0Quick Ratio18.1Cash flow > EarningsY
Price/Sales05-y EBITDA Growth Rate %-24.6Current Ratio18.1Lower Leverage y-yN
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-49.9Higher Current Ratio y-yN
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)-54.2Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M70.8ROI % (ttm)-37.7Gross Margin Increase y-yN

Gurus Latest Trades with ONTY

Number of guru portfolios checked: 56.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
ONTYGeorge Soros 2014-03-31 Buy $1.71 - $3.89
($2.7)
$ 3.0613%New holding, 89600 sh.89,600
ONTYJean-Marie Eveillard 2013-09-30 Add0.01%$1.59 - $2.18
($1.75)
$ 3.0675%Add 75.63%2,275,287
ONTYJean-Marie Eveillard 2013-06-30 Add0.01%$1.57 - $2.63
($2.14)
$ 3.0643%Add 547.75%1,295,499
ONTYJean-Marie Eveillard 2013-03-31 Buy $1.86 - $2.35
($2.09)
$ 3.0646%New holding, 200000 sh.200,000
ONTYJean-Marie Eveillard 2012-03-31 Sold Out -0.0033%$4.16 - $8.96
($6.31)
$ 3.06-52%Sold Out0
ONTYJean-Marie Eveillard 2011-12-31 Add$5.84 - $8.25
($6.85)
$ 3.06-55%Add 33.33%100,000
ONTYJean-Marie Eveillard 2011-09-30 Reduce-0.01%$5.95 - $10.2
($7.49)
$ 3.06-59%Reduce -66.67%75,000
ONTYJean-Marie Eveillard 2011-06-30 Buy 0.01%$3.8 - $9.43
($5.79)
$ 3.06-47%New holding, 225000 sh.225,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

ONTY is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
ONTY George Soros 2014-03-3189,6000.130New Buy
ONTY Jean-Marie Eveillard 2014-03-312,724,9873.850.02+3.81%
Premium Most recent portfolio changes are included for Premium Members only!


ONTY: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
BVF PARTNERS L P/IL10% Owner 2013-11-01Buy129,000$1.7857.3view
BVF PARTNERS L P/IL10% Owner 2013-08-08Buy258,361$1.6569.7view
BVF PARTNERS L P/IL10% Owner 2013-08-01Buy338,087$1.7460.92view
BVF PARTNERS L P/IL10% Owner 2013-06-07Buy214,467$1.8154.7view
Ayer Capital Management, LP10% Owner 2011-06-23Sell28,900$8.74-67.96view
Karan Shashi K.Corporate Controller 2010-09-28Buy5,100$3.41-17.89view
Karan Shashi K.Corporate Controller 2009-08-18Buy5,000$5.07-44.77view

Press Releases about ONTY :

    Quarterly/Annual Reports about ONTY:

    News about ONTY:

    Articles On GuruFocus.com
    Value Betting with Special Situations: Lessons from the World of Gambling Mar 05 2013 
    pro-longs life Jul 30 2011 
    Cubist Pharmaceutical - Acutely Aware May 09 2010 
    Cubist Pharmaceutical - Acutely Aware May 09 2010 
    cooldecency99 note on ONTY May 01 2010 
    creiter note on ONTY Jan 03 2010 

    More From Other Websites
    ONCOTHYREON INC. Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal... Jun 10 2014
    Can the Rally in Oncothyreon (ONTY) Shares Continue? Jun 06 2014
    ONCOTHYREON INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events,... Jun 02 2014
    Oncothyreon Announces Presentation of ONT-10 Data at ASCO Annual Meeting Jun 02 2014
    Oncothyreon Collaborates with Celldex May 30 2014
    Oncothyreon and Celldex to collaborate for clinical trial of ONT-10 and Varlilum May 29 2014
    Oncothyreon and Celldex Therapeutics Announce Collaboration for Combination Immunotherapy Clinical... May 29 2014
    Oncothyreon to Present at Jefferies 2014 Global Healthcare Conference May 28 2014
    ONCOTHYREON INC. Financials May 09 2014
    Oncothyreon's CEO Discusses Q1 2014 Results - Earnings Call Transcript May 01 2014
    Oncothyreon Inc . Discusses Q1 2014 Results (Webcast) May 01 2014
    ONCOTHYREON INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... May 01 2014
    Oncothyreon Reports First Quarter 2014 Financial Results May 01 2014
    Q1 2014 Oncothyreon Inc. Earnings Release - After Market Close May 01 2014
    As Investors Laud Combination Therapies, Oncothyreon's Pipeline Could Come Into Focus Apr 24 2014
    Oncothyreon Announces First Quarter 2014 Financial Results Conference Call Apr 24 2014
    Oncothyreon Announces First Quarter 2014 Financial Results Conference Call Apr 24 2014
    Merck KGaA Starts Study on Tecemotide Apr 08 2014
    Oncothyreon Announces Merck KGaA, Darmstadt, Germany, Initiation of Phase 3 START2 Study with... Apr 07 2014
    Oncothyreon Inc. (ONTY) in Focus: Stock up 6.1% Mar 20 2014

    Add Notes, Comments or Ask Questions

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK
    Email Hide